DK2182960T3 - Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed - Google Patents

Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed

Info

Publication number
DK2182960T3
DK2182960T3 DK08794808.9T DK08794808T DK2182960T3 DK 2182960 T3 DK2182960 T3 DK 2182960T3 DK 08794808 T DK08794808 T DK 08794808T DK 2182960 T3 DK2182960 T3 DK 2182960T3
Authority
DK
Denmark
Prior art keywords
slackness
furrows
formulations
compounds
methods
Prior art date
Application number
DK08794808.9T
Other languages
English (en)
Inventor
Jack Dejovin
Original Assignee
Galderma Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Lab Inc filed Critical Galderma Lab Inc
Application granted granted Critical
Publication of DK2182960T3 publication Critical patent/DK2182960T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
DK08794808.9T 2007-07-27 2008-07-28 Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed DK2182960T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95229807P 2007-07-27 2007-07-27
PCT/US2008/009117 WO2009017705A1 (en) 2007-07-27 2008-07-28 Compounds, formulations, and methods for reducing skin wrinkles, creasing and sagging

Publications (1)

Publication Number Publication Date
DK2182960T3 true DK2182960T3 (da) 2014-05-26

Family

ID=40304650

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08794808.9T DK2182960T3 (da) 2007-07-27 2008-07-28 Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed

Country Status (10)

Country Link
US (3) US20090060852A1 (da)
EP (1) EP2182960B1 (da)
CY (1) CY1115130T1 (da)
DK (1) DK2182960T3 (da)
ES (1) ES2463717T3 (da)
HR (1) HRP20140397T1 (da)
PL (1) PL2182960T3 (da)
PT (1) PT2182960E (da)
SI (1) SI2182960T1 (da)
WO (1) WO2009017705A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20090060852A1 (en) 2007-07-27 2009-03-05 Jack Dejovin Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging
SI2818184T1 (sl) 2007-11-16 2019-03-29 Aclaris Therapeutics, Inc. Sestava in postopki za zdravljenje purpure
EP2262469A4 (en) * 2008-04-15 2013-12-04 Immanence Integrale Dermo Correction Inc SKIN CARE COMPOSITIONS AND METHODS OF USE
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
WO2010115081A2 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Hair-like shaped hydrogels for soft tissue augmentation
WO2010136585A2 (en) * 2009-05-29 2010-12-02 Galderma Research & Development Combination of adrenergic receptor agonist -1 or -2, preferably brimonidine with fillers, preferablyhyaluronic acid
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
HUE033143T2 (en) 2010-03-26 2017-11-28 Galderma Res & Dev Preparations containing brimonidine for the treatment of erythema
JP5747392B2 (ja) 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
RU2571277C2 (ru) 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
WO2013052770A1 (en) 2011-10-05 2013-04-11 Sanders Jennifer L Methods and compositions for treating foot or hand pain
BR112015024113A2 (pt) * 2013-03-20 2017-07-18 Hoffmann La Roche derivados de uréia e seu uso como inibidores da proteína de ligação de ácido graxo (fabp)
ES2693771T3 (es) * 2014-01-29 2018-12-13 Bristol-Myers Squibb Company Inhibidores de aril lactama quinasa

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
FR2648709A1 (fr) * 1989-06-23 1990-12-28 Boehringer Ingelheim France Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants
US5012797A (en) * 1990-01-08 1991-05-07 Montefiore Hospital Association Of Western Pennsylvania Method for removing skin wrinkles
US5254331A (en) * 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
JPH07506367A (ja) * 1992-05-05 1995-07-13 ザ、プロクター、エンド、ギャンブル、カンパニー アクネ治療組成物
US5643586A (en) * 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
DE29612123U1 (de) * 1996-07-11 1996-09-12 Kafl, Johann, 83730 Fischbachau Dermapermeables (hautdurchlässiges) Gel (Salbe) zur subcutanen Lipidmetabolisierung (Unterhautfettverbrennung) und Behandlung von Cellulite
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
ES2220257T1 (es) * 1998-03-11 2004-12-16 Kabushiki Kaisha Soken Agentes normalizadores para la piel.
US5989528A (en) * 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
US6444647B1 (en) * 1999-04-19 2002-09-03 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
JP2004196759A (ja) * 2002-12-18 2004-07-15 Takashi Suzuki ビタミンｋ類とビタミンｅ複合の美肌化粧料
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7288263B2 (en) * 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
US20060275228A1 (en) * 2005-05-09 2006-12-07 Bissett Donald L Skin care compositions containing idebenone
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7252816B1 (en) * 2006-03-29 2007-08-07 Dow Pharmaceutical Sciences Topical acne vulgairs medication with a sunscreen
US20090060852A1 (en) 2007-07-27 2009-03-05 Jack Dejovin Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging

Also Published As

Publication number Publication date
CY1115130T1 (el) 2016-12-14
US20110286945A1 (en) 2011-11-24
PL2182960T3 (pl) 2014-08-29
US20130243837A1 (en) 2013-09-19
HRP20140397T1 (hr) 2014-06-20
EP2182960A1 (en) 2010-05-12
US20090060852A1 (en) 2009-03-05
SI2182960T1 (sl) 2014-07-31
PT2182960E (pt) 2014-06-11
WO2009017705A1 (en) 2009-02-05
EP2182960B1 (en) 2014-03-19
EP2182960A4 (en) 2010-10-27
ES2463717T3 (es) 2014-05-29
US8440688B2 (en) 2013-05-14

Similar Documents

Publication Publication Date Title
DK2182960T3 (da) Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2121139T3 (da) Formulations for cancer treatment
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2358669T3 (da) Alpha-keto-persyrer og fremgangsmåder til fremstilling og anvendelse heraf
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK2229360T3 (da) Indolinonderivater og fremgangsmåde til deres fremstilling
DK3058875T3 (da) System til kosmetisk behandling og billedoptagelse
DK2334378T3 (da) Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
NO20076533L (no) Fremgangsmåte og system for klokkedriftskompensering
BRPI0814188A2 (pt) Formulações
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2432798T3 (da) 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0921947A2 (pt) formulações de proteína terapêutica
BRPI0818598A2 (pt) agentes terapêuticos - 802
DK2158194T3 (da) Derivater af 7-alkynyl-1,8-naphtyridoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf
DK2331057T3 (da) Sammensætninger og fremgangsmåder til modulering af hudpigmentering